文献速递妇科

拓扑替康、紫杉醇和贝伐珠单抗联合治疗改善复发性高级别神经内分泌宫颈癌患者的无进展生存期:一项神经内分泌宫颈肿瘤登记(NeCTuR)研究

Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
PubMed 文献 · Am J Obstet Gynecol · 2022-12-11

该回顾性队列研究基于NeCTuR登记数据,比较62例接受拓扑替康+紫杉醇+贝伐珠单抗方案与56例接受其他化疗的复发性高级别神经内分泌宫颈癌患者。联合方案组中位无进展生存期8.7个月 vs 非联合方案组3.7个月(HR 0.27,95%CI 0.17-0.48,P<.0001),中位总生存期16.8个月 vs 14.0个月(HR 0.87,95%CI 0.55-1.37)。

要点

  • 联合方案组中位无进展生存期8.7个月,非联合方案组3.7个月,疾病进展HR 0.27(95%CI 0.17-0.48;P<.0001)。
  • 联合方案组中位总生存期16.8个月,非联合方案组14.0个月,死亡HR 0.87(95%CI 0.55-1.37)。
  • 联合方案组6个月持续治疗比例31%,非联合方案组67%(P=.0004);1年分别为9% vs 24%(P=.02)。

核心结论

  • 拓扑替康、紫杉醇和贝伐珠单抗联合方案是复发性高级别神经内分泌宫颈癌的有效方案,改善了无进展生存期并降低了疾病进展风险比。

研究设计与样本

  • 回顾性队列研究,使用神经内分泌宫颈肿瘤登记(NeCTuR)中直接摘自英语和西班牙语国家女性病历的数据。
  • 比较62例接受拓扑替康+紫杉醇+贝伐珠单抗作为复发一线或二线治疗的患者与56例接受化疗但未用该联合方案的患者。
  • 化疗持续至疾病进展或出现不可接受的毒性效应。

主要发现

  • 联合方案组中位无进展生存期8.7个月 vs 非联合方案组3.7个月,疾病进展HR 0.27(95%CI 0.17-0.48;P<.0001)。
  • 联合方案组15%患者疾病稳定,39%部分缓解,18%完全缓解。
  • 联合方案组6个月持续治疗比例31% vs 非联合方案组67%(P=.0004),1年分别为9% vs 24%(P=.02)。
  • 联合方案组中位总生存期16.8个月 vs 非联合方案组14.0个月,死亡HR 0.87(95%CI 0.55-1.37)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrent high-grade neuroendocrine cervical cancer has a very poor prognosis and limited active treatment options. OBJECTIVE: This study aimed to evaluate the efficacy of the 3-drug regimen of topotecan, paclitaxel, and bevacizumab in women with recurrent high-grade neuroendocrine cervical cancer. STUDY DESIGN: This retrospective cohort study used data from the Neuroendocrine Cervical Tumor Registry (NeCTuR), which include data abstracted directly from medical records of women diagnosed with high-grade neuroendocrine carcinoma of the cervix from English- and Spanish-speaking countries. The study compared women with recurrent high-grade neuroendocrine cervical cancer who received the topotecan, paclitaxel, and bevacizumab regimen as first- or second-line therapy for recurrence and women with recurrent high-grade neuroendocrine cervical cancer who received chemotherapy but not the topotecan, paclitaxel, and bevacizumab regimen. Patients continued chemotherapy until disease progression or the development of unacceptable toxic effects. Progression-free survival from the start of therapy for recurrence to the next recurrence or death, overall survival from the first recurrence, and response rates were evaluated. RESULTS: The study included 62 patients who received the topotecan, paclitaxel, and bevacizumab regimen as first- or second-line therapy for recurrence and 56 patients who received chemotherapy but not the topotecan, paclitaxel, and bevacizumab regimen for recurrence. The median progression-free survival rates were 8.7 months in the topotecan, paclitaxel, and bevacizumab regimen group and 3.7 months in the non-topotecan, paclitaxel, and bevacizumab regimen group, with a hazard ratio for disease progression of 0.27 (95% confidence interval, 0.17-0.48; P<.0001). In the topotecan, paclitaxel, and bevacizumab regimen group, 15% of patients had stable disease, 39% of patients had a partial response, and 18% of patients had a complete response. Compared with patients in the non-topotecan, paclitaxel, and bevacizumab regimen group, significantly more patients in the topotecan, paclitaxel, and bevacizumab regimen group remained on treatment at 6 months (31% vs 67%, respectively; P=.0004) and 1 year (9% vs 24%, respectively; P=.02). The median overall survival rates were 16.8 months in the topotecan, paclitaxel, and bevacizumab regimen group and 14.0 months in the non-topotecan, paclitaxel, and bevacizumab regimen group, with a hazard ratio for death of 0.87 (95% confidence interval, 0.55-1.37). CONCLUSION: Combination therapy with topotecan, paclitaxel, and bevacizumab was an active regimen in women with recurrent high-grade neuroendocrine cervical cancer and improved progression-free survival while decreasing the hazard ratio for disease progression.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Frumovitz M, Chisholm GB, Jhingran A, et al. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study. Am J Obstet Gynecol. 2022. PMID: 36516952. doi:10.1016/j.ajog.2022.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。